Towards Precritical Medical Therapy of the Abdominal Aortic Aneurysm.

AAA; BM-573; ILT; abdominal aortic aneurysm; antagomir; antioxidant; antiplatelet therapy; inflammation; intraluminal thrombus; metformin; microRNAs; polyphenols; thromboxane A2; Medicine (miscellaneous); Biochemistry, Genetics and Molecular Biology (all); General Biochemistry, Genetics and Molecular Biology

Abstract :

[en] Pharmacotherapy for abdominal aortic aneurysm (AAA) can be useful for prevention, especially in people at higher risk, for slowing down AAA progression, as well as for post-surgery adjuvant treatment. Our review focuses on novel pharmacotherapy approaches targeted towards slowing down progression of AAA, known also as secondary prevention therapy. Guidelines for AAA are not specific to slow down the expansion rate of an abdominal aortic aneurysm, and therefore no medical therapy is recommended. New ideas are urgently needed to develop a novel medical therapy. We are hopeful that in the future, pharmacologic treatment will play a key role in the prevention and treatment of AAA.

Precision for document type :

Review article

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

MUSUMECI, Lucia ; Centre Hospitalier Universitaire de Liège - CHU > > Service de chirurgie cardio-vasculaire et thoracique

Eilenberg, Wolf ; Department of General Surgery, Division of Vascular Surgery, Medical University of Vienna, 1090 Vienna, Austria

Pincemail, Joël ; Centre Hospitalier Universitaire de Liège - CHU > > Service de chimie clinique

Yoshimura, Koichi; Department of Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan ; Graduate School of Health and Welfare, Yamaguchi Prefectural University, Yamaguchi 753-8502, Japan

Sakalihasan, Natzi ; Centre Hospitalier Universitaire de Liège - CHU > > Service de chirurgie cardio-vasculaire et thoracique

Language :

English

Title :

Towards Precritical Medical Therapy of the Abdominal Aortic Aneurysm.

Publication date :

29 November 2022

Journal title :

Biomedicines

eISSN :

2227-9059

Publisher :

MDPI, Switzerland

Volume :

Issue :

Pages :

3066

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://www.mdpi.com/2227-9059/10/12/3066/pdf

Available on ORBi :

since 11 May 2023

Statistics

Number of views

83 (7 by ULiège)

Number of downloads

52 (6 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Sakalihasan N. Michel J.B. Katsargyris A. Kuivaniemi H. Defraigne J.O. Nchimi A. Powell J.T. Yoshimura K. Hultgren R. Abdominal aortic aneurysms Nat. Rev. Dis. Prim. 2018 4 34 10.1038/s41572-018-0030-7 30337540
Yoshimura K. Aoki H. Recent advances in pharmacotherapy development for abdominal aortic aneurysm Int. J. Vasc. Med. 2012 2012 648167 10.1155/2012/648167 22957259
Yoshimura K. Morikage N. Nishino-Fujimoto S. Furutani A. Shirasawa B. Hamano K. Current Status and Perspectives on Pharmacologic Therapy for Abdominal Aortic Aneurysm Curr. Drug Targets 2018 19 1265 1275 10.2174/1389450119666171227223331 29284386
Yoshimura K. Aoki H. Ikeda Y. Fujii K. Akiyama N. Furutani A. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase Nat. Med. 2005 11 1330 1338 10.1038/nm1335
Yoshimura K. Aoki H. Teruyama C. Iijima M. Tsutsumi H. Kuroda S. Kamano H. A Novel Hybrid Drug Delivery System for Treatment of Aortic Aneurysms Int. J. Mol. Sci. 2020 21 5538 10.3390/ijms21155538 32748844
Golledge J. Norman P.E. Murphy M.P. Dalman R.L. Challenges and opportunities in limiting abdominal aortic aneurysm growth J. Vasc. Surg. 2017 65 225 233 10.1016/j.jvs.2016.08.003 27641464
Erbel R. Aboyans V. Boileau C. Bossone E. Bartolomeo R.D. Eggebrecht H. Evangelista A. Falk V. Frank H. Gaemperli O. et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC) Eur. Heart J. 2014 35 2873 2926
Chaikof E.L. Dalman R.L. Eskandari M.K. Jackson B.M. Lee W.A. Mansour M.A. Mastracci T.M. Mell M. Murad M.H. Nguyen L.L. et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm J. Vasc. Surg. 2018 67 2 77.e2 10.1016/j.jvs.2017.10.044 29268916
Wanhainen A. Verzini F. Van Herzeele I. Allaire E. Bown M. Cohnert T. Dick F. van Herwaarden J. Karkos C. Koelemay M. et al. Editor’s Choice—European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms Eur. J. Vasc. Endovasc. Surg. 2019 57 8 93 10.1016/j.ejvs.2018.09.020
Pincemail J. Defraigne J.O. Courtois A. Albert A. Cheramy-Bien J.-P. Sakalihasan N. Abdominal Aortic Aneurysm (AAA): Is There a Role for the Prevention and Therapy Using Antioxidants? Curr. Drug Targets 2018 19 1256 1264 10.2174/1389450118666170918164601
Salmon M. NADPH Oxidases in aortic aneurysms Antioxidants 2002 11 1830 10.3390/antiox11091830 36139902
Kent K.G. Zwolak R.M. Egorova N.N. Riles T.S. Manganaro A. Moskowitz A.J. Gelijns A.C. Greco G. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals J. Vasc. Surg. 2010 52 539 548 10.1016/j.jvs.2010.05.090 20630687
Stackelberg O. Björck M. Larsson S.C. Orsini N. Wolk A. Fruit and vegetable consumption with risk of abdominal aortic aneurysm Circulation 2013 128 795 802 10.1161/CIRCULATIONAHA.112.000728 23960255
Stackelberg O. Björck M. Larsson S.C. Orsini N. Wolk A. Alcohol consumption, specific alcoholic and abdominal aortic aneurysm Circulation 2014 130 646 652 10.1161/CIRCULATIONAHA.113.008279 24965567
Kaluza J. Stackelberg O. Harris H.R. Akesson A. Björck M. Wolk A. Mediterranean diet is associated with reduced risk of abdominal aortic aneurysm in smokers: Results of two prospective cohort studies Eur. J. Vasc. Endovasc. Surg. 2021 62 284 293 10.1016/j.ejvs.2021.04.017
Kaluza J. Stackelberg O. Harris H.R. Akesson A. Björck M. Wolk A. Tea consumption and the risk of abdominal aortic aneurysm BJS 2022 109 346 354 10.1093/bjs/znab468
Hussain T. Tan B. Yin Y. Blachier F. Tossou M.C.B. Rahu N. Oxidative stress and inflammation: What polyphenols can do for us? Oxidative Med. Cell Longev. 2016 2016 7432797 10.1155/2016/7432797
Di Pietro N. Pompea M. Baldassarre A. Cichelli A. Pandolfi A. Formoso G. Pipino C. Role of polyphenols and carotenoids in endothelial dysfunction: An overview from classic to innovative biomarkers Oxidative Med. Cell. Longev. 2020 2020 6381380 10.1155/2020/6381380
DeRoo E. Stranz A. Yang H. Hsieh M. Se C. Zhou T. Endothelial dysfunction in the pathogenesis of abdominal aortic aneurysm Biomolecules 2022 12 509 10.3390/biom12040509 35454098
Toghill B.J. Saratzis A. Harrison S.C. Verissimo A.R. Mallon E.B. Bown M.J. The potential role of DNA methylation in the pathogenesis of abdominal aortic aneurysm Atherosclerosis 2015 241 121 129 10.1016/j.atherosclerosis.2015.05.001
Milan C. Dvoráková A. Skocková V. Kubala L. The role of dietary phenolic compounds in epigenetic modulation involved in inflammatory processes Antioxidants 2020 9 691 10.3390/antiox9080691
Atturu D. Brouilette S. Samani N.J. London N.M.J. Sayers R.D. Rown M.J. Short leukocyte telomere length is associated with abdominal aortic aneurysm (AAA) Eur. J. Vasc. Endovasc. Surg. 2010 39 559 564 10.1016/j.ejvs.2010.01.013 20172749
Maleki M. Khelghati N. Alemi F. Bazdar M. Asemi Z. Majidinia M. Sadeghpoor A. Mahmoodpoor A. Jadidi-Niaragh F. Targhazeh N. et al. Stabilization of telomere by the antioxidant property of polyphenols: Antiaging potential LifeScience 2020 2020 118341 10.1016/j.lfs.2020.118341 32853653
Zhou Y. Jiang Z. Lu Y. Xu Z. Tong R. Shi J. Jia G. Recent advances of natural polyphenols activators for Keap1-Nrf2 signaling pathway Chem. Biodivers. 2019 16 e1900400 10.1002/cbdv.201900400 31482617
Piechota-Polanczyk A. Werner E. Kopacz A. Kloska D. Hajduk K. Dulak J. Jozkowicz A. Inhibition of Nrf2 transcriptional activity favors abdominal aortic aneurysm formation in mice Cardiovasc. Res. 2018 114 S67 S68 10.1093/cvr/cvy060.012
Thompson M.M. Nasim A. Sayers J. Thompson J. Smith G. Luncec J. Bell P.R.F. Oxygen free radical and cytokine inflammation during endovascular and conventional aneurysm repair Eur. J. Vasc. Endovasc. Surg. 1996 12 70 75 10.1016/S1078-5884(96)80278-4 8696901
Khaira H.S. Maxwell S.R. Thomason H. Thorpe G.H. Green M.A. Shearman C.P. Antioxidant depletion during aortic aneurysm repair Br. J. Surg. 1996 83 401 413 10.1002/bjs.1800830335
Aivatidi C. Vourliotakis G. Georgopoulos S. Sigala F. Bastounis E. Papalambros E. Oxidative stress during abdominal aortic aneurysm repair- biomarkers and antioxidant’s protective effect: A review Eur. Rev. Med. Pharmacol. Sci. 2011 15 245 252
Pernicova I. Korbonits M. Metformin--mode of action and clinical implications for diabetes and cancer Rev. Nat. Rev. Endocrinol. 2014 10 143 156 10.1038/nrendo.2013.256
Golledge J. Morris D.R. Pinchbeck J. Rowbotham S. Jenkins J. Bourke M. Bourke B. Norman P.E. Jones R. Moxon J.V. Editor’s Choice—Metformin Prescription is Associated with a Reduction in the Combined Incidence of Surgical Repair and Rupture Related Mortality in Patients with Abdominal Aortic Aneurysm Eur. J. Vasc. Endovasc. Surg. 2019 57 94 101 10.1016/j.ejvs.2018.07.035
Itoga N.K. Rothenberg K.A. Suarez P. Ho T.V. Mell M.W. Xu B. Curtin C.M. Dalman R.L. Metformin prescription status and abdominal aortic aneurysm disease progression in the U.S. veteran population J. Vasc. Surg. 2019 69 710 716.e3 10.1016/j.jvs.2018.06.194 30197158
Golledge J. Moxon J. Pinchbeck J. Anderson G. Rowbotham S. Jenkins J. Bourke M. Bourke B. Dear A. Buckenham T. et al. Association between metformin prescription and growth rates of abdominal aortic aneurysms Br. J. Surg. 2017 104 1486 1493 10.1002/bjs.10587 28650557
Fujimura N. Xiong J. Kettler E.B. Xuan H. Glover K.J. Mell M.W. Xu B. Dalman R.L. Metformin treatment status and abdominal aortic aneurysm disease progression J. Vasc. Surg. 2016 64 46 54.e8 10.1016/j.jvs.2016.02.020
Kristensen K.L. Pottegård A. Hallas J. Rasmussen L.M. Lindholt J.S. Metformin treatment does not affect the risk of ruptured abdominal aortic aneurysms J. Vasc. Surg. 2017 66 768 774.e2 10.1016/j.jvs.2017.01.070 28506478
Pawlyk A.C. Giacomini K.M. McKeon C. Shuldiner A.R. Florez J.C. Metformin pharmacogenomics: Current status and future directions Diabetes 2014 63 2590 2599 10.2337/db13-1367
Isoda K. Young J.L. Zirlik A. MacFarlane L.A. Tsuboi N. Gerdes N. Schönbeck U. Libby P. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells Arterioscler. Thromb. Vasc. Biol. 2006 26 611 617 10.1161/01.ATV.0000201938.78044.75
Wang H. Li T. Chen S. Gu Y. Ye S. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin Arthritis Rheumatol. 2015 67 3190 3200 10.1002/art.39296 26245802
Clinical Trial # NCT03507413. Metformin Therapy in Non-diabetic AAA Patients (MetAAA) Available online: https://clinicaltrials.gov/ct2/show/NCT03507413 (accessed on 25 September 2022)
Clinical Trial # NCT04500756. Limiting AAA with Metformin–LIMIT-Trial Available online: https://clinicaltrials.gov/ct2/show/NCT04500756 (accessed on 25 September 2022)
Clinical Trial # NCT04224051. Metformin for Abdominal Aortic Aneurysm Growth Inhibition Available online: https://clinicaltrials.gov/ct2/show/NCT04224051 (accessed on 25 September 2022)
Zelniker T.A. Wiviott S.D. Raz I. Im K. Goodrich E.L. Bonaca M.P. Mosenzon O. Kato E.T. Cahn A. Furtado R.H.M. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials Lancet 2019 393 31 39 10.1016/S0140-6736(18)32590-X
Liu H. Wei P. Fu W. Xia C. Li Y. Tian K. Li Y. Cheng D. Sun J. Xu Y. et al. Dapagliflozin ameliorates the formation and progression of experimental abdominal aortic aneurysm by reducing aortic inflammation in mice Oxid. Med. Cell. Longev. 2022 2022 8502059 10.1155/2022/8502059 35126822
Michel J.B. Martin-Ventura J.L. Egido J. Sakalihasan N. Treska V. Lindholt J. Allaire E. Thorsteinsdottir U. Cockerill G. Swedenborg J. FAD EU consortium. Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans Rev. Cardiovasc. Res. 2011 90 18 27 10.1093/cvr/cvq337
Nchimi A. Courtois A. El Hachemi M. Touat Z. Drion P. Withofs N. Warnock G. Bahri M.A. Dogné J.M. Cheramy-Bien J.P. et al. Multimodality imaging assessment of the deleterious role of the intraluminal thrombus on the growth of abdominal aortic aneurysm in a rat model Eur. Radiol. 2016 26 2378 2386 10.1007/s00330-015-4010-y 26396112
Boyd A.J. Intraluminal thrombus: Innocent bystander or factor in abdominal aortic aneurysm pathogenesis? JVS Vasc. Sci. 2021 2 159 169 10.1016/j.jvssci.2021.02.001
Touat Z. Ollivier V. Dai J. Huisse M.G. Bezeaud A. Sebbag U. Palombi T. Rossignol P. Meilhac O. Guillin M.C. et al. Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution Am. J. Pathol. 2006 168 1022 1030 10.2353/ajpath.2006.050868 16507915
Dai J. Louedec L. Philippe M. Michel J.B. Houard X. Effect of blocking platelet activation with AZD6140 on development of abdominal aortic aneurysm in a rat aneurysmal model J. Vasc. Surg. 2009 49 719 727 10.1016/j.jvs.2008.09.057 19028049
Fontana P. Zufferey A. Daali Y. Reny J.L. Antiplatelet Therapy: Targeting the TxA2 Pathway J. Cardiovasc. Transl. Res. 2014 7 29 38 10.1007/s12265-013-9529-1
Courtois A. Makrygiannis G. Cheramy-Bien J.P. Purnelle A. Pirotte B. Dogne J.M. Hanson J. Defraigne J.O. Drion P. Sakalihasan N. Therapeutic Applications of Prostaglandins and Thromboxane A2 Inhibitors in Abdominal Aortic Aneurysms Curr. Drug Targets. 2018 19 1247 1255 10.2174/1389450119666171227224314 29284385
Rolin S. Dogné J.M. Michaux C. Delarge J. Masereel B. Activity of a novel dual thromboxane A2 receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles Prostaglandins Leukot. Essent. Fat. Acids 2001 65 67 72 10.1054/plef.2001.0290
Rolin S. Petein M. Tchana-Sato V. Dogne J.M. Benoit P. Lambermont B. Ghuysen A. Kolh P. Masereel B. BM-573, a Dual Thromboxane Synthase Inhibitor and Thromboxane Receptor Antagonist, Prevents Pig Myocardial Infarction Induced by Coronary Thrombosis J. Pharmacol. Exp. Ther. 2003 306 59 65 10.1124/jpet.102.046607
Ghuysen A. Lambermont B. Dogne J.M. Kolh P. Tchana-Sato V. Morimont P. Magis D. Hanson J. Segers P. D’Orio V. Effect of BM-573 [N-Terbutyl-N’-[2-(4′-methylphenylamino)-5- nitro-benzenesulfonyl]urea], a Dual Thromboxane Synthase Inhibitor and Thromboxane Receptor Antagonist, in a Porcine Model of Acute Pulmonary Embolism J. Pharmacol. Exp. Ther. 2004 310 964 972 10.1124/jpet.104.066852
Dogné J.M. Hanson J. de Leval X. Kolh P. Tchana-Sato V. de Leval L. Rolin S. Ghuysen A. Segers P. Lambermont B. et al. Pharmacological characterization of N-tert-butyl-N′-[2-(4′-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time J. Pharmacol. Exp. Ther. 2004 309 498 505 14742735
de Leval X. Dassesse T. Dogné J.M. Waltregny D. Bellahcène A. Benoit V. Pirotte B. Castronovo V. Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents J. Pharmacol. Exp. Ther. 2006 318 1057 1067 10.1124/jpet.106.101188 16720756
Cyrus T. Yao Y. Ding T. Dogné J.M. Praticò D. Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice Blood 2007 109 3291 3296 10.1182/blood-2006-08-044990 17158227
Cherdon C. Rolin S. Hanson J. Ooms A. de Leval L. Drion P. Michiels C. Pirotte B. Masereel B. Sakalihassan N. et al. BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase Prostaglandins Other Lipid Mediat. 2011 94 124 132 10.1016/j.prostaglandins.2011.03.001 21397034
Maegdefessel L. Dalman R.L. Tsao P.S. Pathogenesis of Abdominal Aortic Aneurysms: MicroRNAs, Proteases, Genetic Associations Annu. Rev. Med. 2014 65 49 62 10.1146/annurev-med-101712-174206
Maegdefessel L. Spin J.M. Raaz U. Eken S.M. Toh R. Azuma J. Adam M. Nagakami F. Heymann H.M. Chernugobova E. et al. miR-24 limits aortic vascular inflammation and murine abdominal aneurysm development Nat. Comm. 2014 5 5214 10.1038/ncomms6214
Lu T.X. Rothenberg M.E. MicroRNA J. Allergy Clin. Immun. 2018 141 1202 1207 10.1016/j.jaci.2017.08.034
O’Brien J. Hayder H. Zayed Y. Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation Front. Endocrinol. 2018 9 402 10.3389/fendo.2018.00402 30123182
Miyake T. Miyake T. Kurashiki T. Morishita R. Molecular Pharmacological Approaches for Treating Abdominal Aortic Aneurysm Ann. Vasc. Dis. 2019 12 137 146 10.3400/avd.ra.18-00076
Yamada Y. Nucleic Acid Drugs-Current Status, Issues, and Expectations for Exosomes Cancers 2021 13 5002 10.3390/cancers13195002 34638486
Zhu Y. Zhu L. Wang X. Jin H. RNA-based therapeutics: An overview and prospectus Cell Death Dis. 2022 13 644 10.1038/s41419-022-05075-2 35871216
Nosoudi N. Nahar-Gohad P. Sinha A. Chowdhury A. Gerard P. Carsten C.G. Gray B.H. Vyavahare N.R. Prevention of abdominal aortic aneurysm progression by targeted inhibition of matrix metalloproteinase activity with batimastat-loaded nanoparticles Circ. Res. 2015 117 e80 e89 10.1161/CIRCRESAHA.115.307207 26443597
Lu S. Wang R. Fu W. Si Y. Applications of Extracellular Vesicles in Abdominal Aortic Aneurysm Front. Cardiovasc. Med. 2022 9 927542 10.3389/fcvm.2022.927542 35711380
Maegdefessel L. Azuma J. Toh R. Merk D.R. Deng A. Chin J.T. Raaz U. Schoelmerich A.M. Raiesdana A. Leeper N.J. et al. Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development J. Clin. Investig. 2012 122 497 506 10.1172/JCI61598 22269326
Maegdefessel L. Azuma J. Toh R. Deng A. Merk D.R. Raiesdana A. Leeper N.J. Raaz U. Schoelmerich A.M. McConnell M.V. et al. MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion Sci. Transl. Med. 2012 4 122ra22 10.1126/scitranslmed.3003441
Courtois A. Nusgens B. Garbacki N. Hustinx R. Gomez P. Defraigne J.O. Colige A.C. Sakalihasan N. Circulating microRNAs signature correlates with positive [18F]fluorodeoxyglucose-positron emission tomography in patients with abdominal aortic aneurysm J. Vasc. Surg. 2018 67 585 595.e3 10.1016/j.jvs.2016.12.112
Wanhainen A. Mani K. Vorkapic E. De Basso R. Björck M. Länne T. Wågsäter D. Screening of circulating microRNA biomarkers for prevalence of abdominal aortic aneurysm and aneurysm growth Atherosclerosis 2017 256 82 88 10.1016/j.atherosclerosis.2016.11.007
Rayner K.J. Suarez Y. Davalos A. Parathath S. Fitzgerald M.L. Tamehiro N. Fisher E.A. Moore K.J. Fernández-Hernando C. MiR-33 contributes to the regulation of cholesterol homeostasis Science 2010 328 1570 1573 10.1126/science.1189862
Nakao T. Horie T. Baba O. Nishiga M. Nishino T. Izuhara M. Kuwabara Y. Nishi H. Usami S. Nakazeki F. et al. Genetic Ablation of MicroRNA-33 Attenuates Inflammation and Abdominal Aortic Aneurysm Formation via Several Anti-Inflammatory Pathways Arterioscler. Thromb. Vasc. Biol. 2017 37 2161 2170 10.1161/ATVBAHA.117.309768
Kumar S. Boon R.A. Maegdefessel L. Dimmeler S. Jo H. Role of Noncoding RNAs in the Pathogenesis of Abdominal Aortic Aneurysm Circ. Res. 2019 124 619 630 10.1161/CIRCRESAHA.118.312438